NCT02342782View on ClinicalTrials.gov

Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 8, 2020

Primary Completion Date

September 18, 2020

Study Completion Date

November 18, 2024

Conditions
Mature T-Cell and NK-Cell Non-Hodgkin LymphomaRecurrent Mature T- and NK-Cell Non-Hodgkin LymphomaRefractory Mature T-Cell and NK-Cell Non-Hodgkin LymphomaRecurrent Cutaneous T-Cell Non-Hodgkin LymphomaRefractory Cutaneous T-Cell Non-Hodgkin Lymphoma
Interventions
BIOLOGICAL

Yttrium Y 90 Basiliximab

Given IV

DRUG

Carmustine

Given IV

DRUG

Etoposide

Given IV

DRUG

Cytarabine

Given IV

DRUG

Melphalan

Given IV

PROCEDURE

Autologous Hematopoietic Stem Cell Transplantation

Undergo AHCT

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT02342782 - Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter